期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 66, 期 5, 页码 3195-3211出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c02012
关键词
-
MC4R is involved in the regulation of appetite and food intake, and deficiency in MC4R signaling leads to weight gain in humans. Through screening and optimization, a series of orally bioavailable, small-molecule MC4R antagonists were identified, and compound 23, a potent and selective MC4R antagonist, showed significant efficacy in an aged rat model of cachexia and has progressed into clinical trials.
The melanocortin-4 receptor (MC4R) is a centrally expressed, class A GPCR that plays a key role in the regulation of appetite and food intake. Deficiencies in MC4R signaling result in hyperphagia and increased body mass in humans. Antagonism of MC4R signaling has the potential to mitigate decreased appetite and body weight loss in the setting of anorexia or cachexia due to underlying disease. Herein, we report on the identification of a series of orally bioavailable, small-molecule MC4R antagonists using a focused hit identification effort and the optimization of these antagonists to provide clinical candidate 23. Introduction of a spirocyclic conformational constraint allowed for simultaneous optimization of MC4R potency and ADME attributes while avoiding the production of hERG active metabolites observed in early series leads. Compound 23 is a potent and selective MC4R antagonist with robust efficacy in an aged rat model of cachexia and has progressed into clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据